4.1 Review

Voltage-gated Potassium Channel-associated Limbic Encephalitis in the West of Scotland: Case Reports and Literature Review

Journal

SCOTTISH MEDICAL JOURNAL
Volume 54, Issue 4, Pages 27-31

Publisher

SCOTTISH MEDICAL JOURNAL
DOI: 10.1258/rsmsmj.54.4.27

Keywords

Limbic encephalitis; temporal lobe; amnesia; voltage-gated potassium channel

Ask authors/readers for more resources

Background and Aims The syndrome of limbic encephalitis (LE) associated with antibodies against voltage-gated potassium channels (VGKC-LE) has recently been described. The number of published cases is however small. We therefore aimed to review all cases seen at our centre and compare with published cases. Methods Retrospective cases of VGKC-LE were identified using a questionnaire to Neurologists at the Southern General hospital, Glasgow, and by reviewing patients with a positive VGKC antibody test (2002-2007). Case-note review of identified cases and a literature review of all published cases of VGKC-LE were performed. Results Seven cases were identified (four female, age range 5181). Patients presented sub-acutely with seizures and anterograde memory loss. Five patients had medial temporal lobe change on cranial imaging. No paraneoplastic cases were identified. 5/7 patients made some improvement with immunotherapy. In 2006, 3/18 (17%) patients with a coded discharge of encephalitis were diagnosed with VGKC-LE. The literature review revealed 40 patients with VGKC-LE. Age, gender or VGKC level did not predict likelihood for a significant recovery. Patients treated :55 months of symptom onset with immunotherapy were more likely to make a significant recovery (83% vs. 45%, p=0.04). Conclusion VGKC-LE is being increasingly diagnosed and is best identified early and treated with immunotherapy to offer the greatest chance of recovery. This series and literature review expands the current published evidence in VGKC-LE.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.1
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Multidisciplinary Sciences

Consent for Brain Tissue Donation after Intracerebral Haemorrhage: A Community-Based Study

Neshika Samarasekera, Christine Lerpiniere, Arthur F. Fonville, Andrew J. Farrall, Joanna M. Wardlaw, Philip M. White, Antonia Torgersen, James W. Ironside, Colin Smith, Rustam Al-Shahi Salman

PLOS ONE (2015)

Article Clinical Neurology

Influence of Intracerebral Hemorrhage Location on Incidence, Characteristics, and Outcome Population-Based Study

Neshika Samarasekera, Arthur Fonville, Christine Lerpiniere, Andrew J. Farrall, Joanna M. Wardlaw, Philip M. White, Colin Smith, Rustam Al-Shahi Salman

STROKE (2015)

Letter Clinical Neurology

Potential disease-modifying effects of selective serotonin reuptake inhibitors in multiple sclerosis: systematic review and meta-analysis

P. Foley, A. Lawler, S. Chandran, G. Mead

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2014)

Review Neuroimaging

Pain in multiple sclerosis: A systematic review of neuroimaging studies

D. Seixas, P. Foley, J. Palace, D. Lima, I. Ramos, I. Tracey

NEUROIMAGE-CLINICAL (2014)

Article Infectious Diseases

Case report: meningitis as a presenting feature of anti-NMDA receptor encephalitis

Maria Stavrou, Jing Ming Yeo, Alexander David Slater, Oliver Koch, Sarosh Irani, Peter Foley

BMC INFECTIOUS DISEASES (2020)

Article Clinical Neurology

Association between Computed Tomographic Biomarkers of Cerebral Small Vessel Diseases and Long-Term Outcome after Spontaneous Intracerebral Hemorrhage

Mark A. Rodrigues, Neshika E. Samarasekera, Christine Lerpiniere, Luke A. Perry, Tom J. Moullaali, James J. M. Loan, Joanna M. Wardlaw, Rustam Al-Shahi Salman

Summary: This study highlights the association between SVD biomarkers on diagnostic brain CT and long-term outcome after intracerebral hemorrhage.

ANNALS OF NEUROLOGY (2021)

Article Clinical Neurology

Efficacy of Fluoxetine, Riluzole and Amiloride in treating neuropathic pain associated with secondary progressive multiple sclerosis. Pre-specified analysis of the MS-SMART double-blind randomised placebo-controlled trial

Peter Foley, Richard A. Parker, Floriana de Angelis, Peter Connick, Siddharthan Chandran, Carolyn Young, Christopher J. Weir, Jeremy Chataway

Summary: The use of Fluoxetine, Riluzole, or Amiloride did not result in significant improvement of neuropathic pain symptoms in adults with secondary progressive MS, compared to a placebo.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2022)

Article Medicine, General & Internal

FutureMS cohort profile: a Scottish multicentre inception cohort study of relapsing-remitting multiple sclerosis

Patrick K. A. Kearns, Sarah J. Martin, Jessie Chang, Rozanna Meijboom, Elizabeth N. York, Yingdi Chen, Christine Weaver, Amy Stenson, Katarzyna Hafezi, Stacey Thomson, Elizabeth Freyer, Lee Murphy, Adil Harroud, Peter Foley, David Hunt, Margaret McLeod, Jonathon O'Riordan, F. J. Carod-Artal, Niall J. J. MacDougall, Sergio E. Baranzini, Adam D. Waldman, Peter Connick, Siddharthan Chandran

Summary: This study aims to explore the pathobiology and determinants of disease heterogeneity in multiple sclerosis (MS) by integrating clinical phenotyping, imaging, genetics, and biomarkers. Recruitment, baseline assessment, and one-year follow-up have been completed. Longer-term follow-up is planned.

BMJ OPEN (2022)

Article Clinical Neurology

The influence of disease-modifying therapy on hidden disability burden in people with newly diagnosed relapsing-remitting multiple sclerosis

Stella A. Glasmacher, Patrick K. A. Kearns, Zackary Hassan, Peter Connick, Simone Tauber, Kathrin Reetz, Peter Foley, Siddharthan Chandran

Summary: In addition to motor disability, people with multiple sclerosis often experience hidden disabilities such as depression, anxiety, fatigue, sleep disturbances, cognitive impairment, and pain. This study explored the changes in hidden disability burden during the early post-diagnostic period and examined the effects of disease modifying therapies. The results showed that disease modifying therapies did not have a significant impact on hidden disability burden, although a small group of patients who received specific treatments did experience improvements.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2022)

Article Clinical Neurology

Chronic meningitis, seizures and myoclonus

James Joseph McDonald, Matthew Jones, Colin Smith, Peter L. Foley, Liam Lee, Richard Davenport

Summary: This article reports a clinicopathological conference presented at the Edinburgh Clinical Neurology Course 2021, discussing the case of a 70-year-old retired male plumber who was admitted with reduced consciousness, confusion, and headache, and later developed encephalopathy, seizures, and myoclonus. Despite treatment, the patient passed away 10 weeks later.

PRACTICAL NEUROLOGY (2022)

Review Medicine, General & Internal

Systematic, comprehensive, evidence-based approach to identify neuroprotective interventions for motor neuron disease: using systematic reviews to inform expert consensus

Charis Wong, Jenna M. Gregory, Jing Liao, Kieren Egan, Hanna M. Vesterinen, Aimal Ahmad Khan, Maarij Anwar, Caitlin Beagan, Fraser S. Brown, John Cafferkey, Alessandra Cardinali, Jane Yi Chiam, Claire Chiang, Victoria Collins, Joyce Dormido, Elizabeth Elliott, Peter Foley, Yu Cheng Foo, Lily Fulton-Humble, Angus B. Gane, Stella A. Glasmacher, Aine Heffernan, Kiran Jayaprakash, Nimesh Jayasuriya, Amina Kaddouri, Jamie Kiernan, Gavin Langlands, D. Leighton, Jiaming Liu, James Lyon, Arpan R. Mehta, Alyssa Meng, Vivienne Nguyen, Na Hyun Park, Suzanne Quigley, Yousuf Rashid, Andrea Salzinger, Bethany Shiell, Ankur Singh, Tim Soane, Alexandra Thompson, Olaf Tomala, Fergal M. Waldron, Bhuvaneish T. Selvaraj, Jeremy Chataway, Robert Swingler, Peter Connick, Suvankar Pal, Siddharthan Chandran, Malcolm Macleod

Summary: This study presents a systematic and structured evidence-based approach to select the first two drugs for evaluation in the MND-SMART trial. Through a comprehensive evaluation of clinical studies and animal models, memantine and trazodone were selected as the first two drugs based on supportive evidence.

BMJ OPEN (2023)

Article Clinical Neurology

Network analysis characterizes key associations between subjective fatigue and specific depressive symptoms in early relapsing-remitting multiple sclerosis

Yuan-Ting Chang, Patrick K. A. Kearns, Alan Carson, David C. Gillespie, Rozanna Meijboom, Agniete Kampaite, Maria del C. Valdes Hernandez, Christine Weaver, Amy Stenson, Niall MacDougall, Jonathan O'Riordan, Margaret Ann Macleod, Francisco Javier Carod-Artal, Peter Connick, Adam D. Waldman, Siddharthan Chandran, Peter Foley

Summary: This study used a multivariate network approach to quantify relationships between fatigue and other variables in early multiple sclerosis (MS). The results showed strong connections between fatigue severity and depression, and four specific depressive symptoms were linked to fatigue. These findings are important for further research and treatment of MS-related fatigue.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2023)

Article Clinical Neurology

Coupling cognitive and brainstem dysfunction in multiple sclerosis-related chronic neuropathic limb pain

Peter Foley, Yazhuo Kong, Ramune Dirvanskiene, Maria Valdes-Hernandez, Matteo Bastiani, Jonathan Murnane, Robin Sellar, Neil Roberts, Cyril Pernet, Christopher Weir, Thomas Bak, Lesley Colvin, Siddharthan Chandran, Marie Fallon, Irene Tracey

Summary: This study reports the dysfunction of descending pain modulation in multiple sclerosis patients with chronic neuropathic pain, showing reduced functional connectivity in specific brain structures and executive dysfunction. The findings highlight the close relationship between cognition, functioning of the descending pain modulatory system, and chronic pain conditions, providing insights for potential pharmacological and cognitive interventions.

BRAIN COMMUNICATIONS (2022)

Article Clinical Neurology

MRI-derived g-ratio and lesion severity in newly diagnosed multiple sclerosis

Elizabeth N. York, Sarah-Jane Martin, Rozanna Meijboom, Michael J. Thrippleton, Mark E. Bastin, Edwin Carter, James Overell, Peter Connick, Siddharthan Chandran, Adam D. Waldman, David P. J. Hunt

Summary: The study shows that reduced myelin integrity is associated with axonal damage even at the diagnosis of multiple sclerosis. The MRI-derived g-ratio may provide useful additional information regarding lesion severity and help identify individuals with a high degree of axonal damage at disease onset. The correlation between g-ratio and plasma neurofilament levels suggests a potential biomarker for disease progression and severity in MS patients.

BRAIN COMMUNICATIONS (2021)

Article Clinical Neurology

Antibodies to the Caspr1/contactin-1 complex in chronic inflammatory demyelinating polyradiculoneuropathy

Elba Pascual-Goni, Janev Fehmi, Cinta Lleixa, Lorena Martin-Aguilar, Jerome Devaux, Romana Hoftberger, Emilien Delmont, Kathrin Doppler, Claudia Sommer, Aleksandar Radunovic, Alejandra Carvajal, Shane Smyth, Laura Williams, Radim Mazanec, Veronika Potockova, Nigel Hinds, Julien Cassereau, Karine Viala, Mathilde Lefilliatre, Guillaume Nicolas, Peter Foley, Frank Leypoldt, Stephen Keddie, Michael P. Lunn, Fritz Zimprich, Vharoon Sharma Nunkoo, Wolfgang N. Loscher, Laura Martinez-Martinez, Jordi Diaz-Manera, Ricard Rojas-Garcia, Isabel Illa, Simon Rinaldi, Luis Querol

Summary: In patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), a small percentage have antibodies targeting the Caspr1/CNTN1 complex, showing similar clinical and serological features, forming a distinct subgroup within the CIDP syndrome.

BRAIN (2021)

No Data Available